Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Baris Gencer

Showing results (11-20 of 179) with videos related to

Pageof 18
Sort By:
Thrombosis and Haemostasis|September 2, 2019
Gender Specificity and Interpretation of Functional Cardiac Imaging: Let's Talk about SexBaris Gencer, François Mach
Drugs|January 10, 2020
Potential of Lipoprotein(a)-Lowering Strategies in Treating Coronary Artery DiseaseBaris Gencer, François Mach
European Heart Journal|November 4, 2022
Inclisiran in primary prevention: reality or fiction?Baris Gencer, François Mach
European Journal of Preventive Cardiology|July 15, 2025
What matters for LDL-C lowering therapies: the absolute or the relative risk reduction?Baris Gencer, Georg Ehret
Current Medicinal Chemistry|August 5, 2021
PCSK9 Inhibition could be Effective for Acute Myocardial InfarctionBaris Gencer, François Mach
European Journal of Clinical Investigation|February 4, 2022
2021 European guidelines on cardiovascular prevention: Challenges for an evidence-based patient careBaris Gencer, Elena Tessitore
European Heart Journal|January 19, 2018
So low… so far so good: neurocognitive impact of lowering LDL-C levels with PCSK9 inhibitorsBaris Gencer, François Mach
European Heart Journal|April 2, 2015
Sweetless'n low LDL-C targets for PCSK9 treatmentBaris Gencer, François Mach
Open Heart|October 6, 2015
Coronary artery disease is associated with persistent lower quality of life in womenBaris Gencer, François Girardin
Expert Review of Cardiovascular Therapy|June 16, 2025
Determining major adverse cardiovascular event risk of beta-blocker discontinuation after acute coronary syndromesNicolas Johner, Baris Gencer
Pageof 18

Showing results (11-20 of 179) with videos related to

Sort By:
Pageof 18
Thrombosis and Haemostasis|September 2, 2019
Gender Specificity and Interpretation of Functional Cardiac Imaging: Let's Talk about SexBaris Gencer, François Mach
Drugs|January 10, 2020
Potential of Lipoprotein(a)-Lowering Strategies in Treating Coronary Artery DiseaseBaris Gencer, François Mach
European Heart Journal|November 4, 2022
Inclisiran in primary prevention: reality or fiction?Baris Gencer, François Mach
European Journal of Preventive Cardiology|July 15, 2025
What matters for LDL-C lowering therapies: the absolute or the relative risk reduction?Baris Gencer, Georg Ehret
Current Medicinal Chemistry|August 5, 2021
PCSK9 Inhibition could be Effective for Acute Myocardial InfarctionBaris Gencer, François Mach
European Journal of Clinical Investigation|February 4, 2022
2021 European guidelines on cardiovascular prevention: Challenges for an evidence-based patient careBaris Gencer, Elena Tessitore
European Heart Journal|January 19, 2018
So low… so far so good: neurocognitive impact of lowering LDL-C levels with PCSK9 inhibitorsBaris Gencer, François Mach
European Heart Journal|April 2, 2015
Sweetless'n low LDL-C targets for PCSK9 treatmentBaris Gencer, François Mach
Open Heart|October 6, 2015
Coronary artery disease is associated with persistent lower quality of life in womenBaris Gencer, François Girardin
Expert Review of Cardiovascular Therapy|June 16, 2025
Determining major adverse cardiovascular event risk of beta-blocker discontinuation after acute coronary syndromesNicolas Johner, Baris Gencer
Pageof 18